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Abstract
Background
A false-negative case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection is defined as a person with suspected infection and an initial negative result by
reverse transcription-polymerase chain reaction (RT-PCR) test, with a positive result on a
subsequent test. False-negative cases have important implications for isolation and risk
of transmission of infected people and for the management of coronavirus disease 2019
(COVID-19). We aimed to review and critically appraise evidence about the rate of RT-PCR
false-negatives at initial testing for COVID-19.
Methods
We searched MEDLINE, EMBASE, LILACS, as well as COVID-19 repositories, including
the EPPI-Centre living systematic map of evidence about COVID-19 and the Coronavirus
Open Access Project living evidence database. Two authors independently screened and
selected studies according to the eligibility criteria and collected data from the included stud-
ies. The risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) tool. We calculated the proportion of false-negative test results using
a multilevel mixed-effect logistic regression model. The certainty of the evidence about
false-negative cases was rated using the GRADE approach for tests and strategies. All
information in this article is current up to July 17, 2020.
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Results
We included 34 studies enrolling 12,057 COVID-19 confirmed cases. All studies were
affected by several risks of bias and applicability concerns. The pooled estimate of false-
negative proportion was highly affected by unexplained heterogeneity (tau-squared = 1.39;
90% prediction interval from 0.02 to 0.54). The certainty of the evidence was judged as very
low due to the risk of bias, indirectness, and inconsistency issues.
Conclusions
There is substantial and largely unexplained heterogeneity in the proportion of false-nega-
tive RT-PCR results. The collected evidence has several limitations, including risk of bias
issues, high heterogeneity, and concerns about its applicability. Nonetheless, our findings
reinforce the need for repeated testing in patients with suspicion of SARS-Cov-2 infection
given that up to 54% of COVID-19 patients may have an initial false-negative RT-PCR (very
low certainty of evidence).
Systematic review registration
Protocol available on the OSF website: https://tinyurl.com/vvbgqya.
Introduction
Accurate laboratory tests are essential for the diagnosis and management of emerging infec-
tious diseases. On December 31, 2019, the World Health Organization (WHO) was alerted
about a cluster of patients with pneumonia in Wuhan City, Hubei province, China [1]. Chi-
nese authorities confirmed, a week later, an outbreak of a novel coronavirus. The virus has
been named as severe acute respiratory coronavirus 2 (SARS-CoV-2) (SARS-CoV-2) [2], and
the clinical disease that it causes is coronavirus disease 2019 (COVID-19), which has become a
worldwide public health emergency and reached pandemic status [3, 4]. By October 16 2020,
there was a total of 39.023.292 confirmed cases, and 1.099.586 confirmed cases worldwide [5].
Clinical suspicion of COVID-19 is based primarily on respiratory symptoms such as fever,
cough, and shortness of breath as primary manifestations [6, 7]. The spectrum of symptoms
and clinical signs associated with COVID-19 has expanded with increasing knowledge about
SARS-CoV-2. Although most of the cases present mild symptoms, some cases have developed
pneumonia, severe respiratory diseases, kidney failure or heart failure [8–11]. The death rate
from SARS-CoV-2 infection is estimated to be of 0.68% (95% CI from 0.53 to 0.82) [12]
SARS-CoV-2 mainly spreads through person-to-person contact via respiratory droplets from
coughing and sneezing, and through surfaces that have been contaminated with these droplets
[13]. A proportion of cases will, however, remain asymptomatic throughout the course of
infection, estimated as around 20% in a range of settings [14, 15].
Because the signs of infection mentioned above are non-specific, confirmation of cases is
currently based on the detection of nucleic acid amplification tests that detect viral ribonucleic
acid (RNA) sequences by reverse transcription-polymerase chain reaction (RT-PCR) [16]. Dif-
ferent RT-PCR assays have been proposed, all of which include the N gene that codes for the
viral nucleocapsid. Other alternative targets are the E gene, for the viral envelope; the S gene
for the spike protein; and the Hel gene for the RNA polymerase gene (RdRp/Helicase) [16, 17].
Molecular criteria for in vitro diagnosis of COVID-19 disease are heterogeneous, and usually
require the detection of two or more SARS-CoV-2 genes [18].
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A person with a negative RT-PCR result at initial testing, with a subsequent positive test
result, is considered as a false-negative diagnosis. Clinical practice guidelines and consensus
statements recommend repeated RT-PCR testing to confirm a clinical diagnosis, especially in
the presence of symptoms associated with COVID-19 [19–23]. Researchers have suggested
that these failures in SARS-CoV-2 detection are related to multiple preanalytical and analytical
factors, such as lack of standardisation for specimen collection, delays or poor storage condi-
tions before arrival in the laboratory, the use of inadequately validated assays, contamination
during the procedure, insufficient viral specimens and load, the incubation period of the dis-
ease, and the presence of mutations that escape detection or PCR inhibitors [18, 24].
The availability of accurate laboratory tools for COVID-19 is essential for case identifica-
tion, contact tracing, and optimisation of infection control measures, as it was shown by previ-
ous epidemics caused by SARS-CoV and the Middle East Respiratory Syndrome Coronavirus
(MERS-CoV) [25–27]. Due to the significant burden on health systems around the globe
caused by the COVID-19 pandemic, and the potential consequences at several levels of missing
a COVID-19 case, we aimed to obtain through a systematic review of the literature, a summary
estimate of the proportion of false-negatives related to the detection of SARS-CoV-2 using
RT-PCR assays at the first healthcare encounter (initial testing).
Materials and methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diag-
nostic Test Accuracy Studies (PRISMA-DTA) to report this review [28]. This manuscript
reflects the third update of our literature searches with information current up to July 2020. The
initial review protocol, previous reports of findings by date of search and supplementary mate-
rial are available in the Open Science Framework repository (https://tinyurl.com/vvbgqya).
Criteria for considering studies for this review
We included observational studies (including diagnostic test accuracy studies) reporting the
initial use of RT-PCR to detect SARS-CoV-2 RNA in patients with suspected infection by clini-
cal or epidemiological criteria. We primarily aimed to include studies enrolling consecutive
patients who received an RT-PCR test at the first healthcare encounter (initial testing), with
further confirmation of SARS-CoV-2 infection of initial negative cases by an additional
RT-PCR evaluation. We did not impose limits by age, gender, or study location.
We aimed to include all types of RT-PCR kits, regardless of the brand or manufacturer, the
RNA extraction method used, the number of target gene assays assessed, or the cycle threshold
value for positivity. We excluded studies that focused on other populations or reporting sam-
ples/specimens instead of patients (such as monitoring or discharge of COVID-19 confirmed
cases, population screening and patients with comorbidities), studies only providing the abso-
lute number of false-negatives or without clear information about numerical information, and
studies reporting validation of novel assays or comparing sample collection/sample specimens
(i.e. focus on agreement). Full eligibility criteria can be found in the S1 File.
Search methods for identification of studies
We carried out a comprehensive and sensitive search strategy based on search terms developed
for the COVID-19 Open Access Project by researchers and librarians at the Institute of Social
and Preventive Medicine, University of Bern (https://ispmbern.github.io/covid-19/living-
review/collectingdata.html) in the following databases:
• MEDLINE (Ovid SP, 1946 to July 17, 2020)
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• Embase (Ovid SP, 1982 to July 17, 2020)
• LILACS (iAH English) (BIREME, 1982 to July 17, 2020)
We did not apply any language restrictions to electronic searches (S2 File). As additional
sources of potential studies, we searched in repositories of preprint articles, registries for ongo-
ing or recently completed clinical trials (clinicaltrials.gov; the World Health Organization
International Trials Registry and Platform, and the ISRCTN Registry), and the reference lists
of all relevant papers. We also screened the following resources for additional information:
• The WHO Database of publications on coronavirus disease (COVID-19) (Available on
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-
novel-coronavirus-2019-ncov).
• The LOVE (Living OVerview of Evidence) centralised repository developed by Epistemoni-
kos (available on https://app.iloveevidence.com/topics)
• The Living systematic map of the evidence about COVID-19 produced by the Evidence for
Policy and Practice Information and Co-ordinating Centre (EPPI-Centre) [29].
• The COVID-19 Open Access Project Living Evidence on COVID-19, developed at the Insti-
tute of Social and Preventive Medicine, University of Bern (available on https://ispmbern.
github.io/covid-19/)
Data collection and analysis
For the selection of eligible studies, two out of three reviewers (IAR, DBG or PZA) indepen-
dently screened the search results based on their titles and abstract. We retrieved the full-text
copy of each study assessed as potentially eligible, and two out of three reviewers (IAR, DBG
or PZA) confirmed eligibility according to the selection criteria. In case of disagreements, we
reached consensus by discussion. For data extraction, one reviewer extracted qualitative and
quantitative data from eligible studies, and an additional reviewer checked all the extracted
information for accuracy. We contacted study authors to supply missing information about
critical characteristics of included studies.
Assessment of methodological quality
Two authors independently assessed the risk of bias of included studies, and disagreements
were resolved through discussion. We evaluated the methodological quality using the Quality
Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool [30]. We decided to also apply
the QUADAS-2 tool for case series studies due to the lack of tools to assess the risk of bias asso-
ciated with these studies. However, for a more comprehensive assessment of the limitations of
the included studies, we adapted the Joanna Briggs Institute (JBI) Critical Appraisal Checklist
for Case Series [31]. This tool included items about inclusion criteria, measurement of asymp-
tomatic status, follow-up of the course of the disease, and availability of numerator and
denominator. We added questions about the representativeness of the source and target popu-
lations as well.
Statistical analysis and data synthesis
For all included studies, we extracted data to calculate the proportion of false-negative results.
The numerator (false-negative cases) was the number of cases initially considered negative by
RT-PCR. The denominator was the total number of SARS-CoV-2 infections, detected on an
PLOS ONE Systematic review about false-negative of initial RT-PCR for COVID-19 diagnosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0242958 December 10, 2020 4 / 19
additional test by RT-PCR, using the same or a different assay. We presented the results of esti-
mated proportions (with 95% CIs) in a forest plot to assess the between-study variability. We
aimed to calculate a summary estimate of the false-negative rate with the corresponding 95%
CI using a multilevel mixed-effect logistic regression model in Stata 161. This method allowed
us to estimate the between-study heterogeneity from the variance of study-specific random
intercepts. We computed 90% prediction intervals to include the between-study variation. The
90% prediction interval shows the range of true false-negative proportions that can be expected
in 90% of future settings, comparable to the ones included in the meta-analysis. We expressed
heterogeneity in primary study results using the Tau-square statistic.
We planned to investigate the potential sources of heterogeneity using a descriptive
approach and performing a random-effects meta-regression analysis, including covariates, one
at each time, into the logistic model. Anticipated sources of heterogeneity included the type of
specimen collected, the presence or not of clinical findings, the number of RNA targets genes
under assessment, and the time of symptom evolution.
Summary of findings and certainty of the evidence
We rated the certainty of the evidence about false-negative cases following the GRADE
approach for tests and strategies [32, 33]. We assessed the quality of evidence as high, moder-
ate, low, or very low, depending on several factors, including risk of bias, imprecision, incon-
sistency, indirectness, and publication bias. We illustrate the consequences of the numerical
findings in a population of 100 tested, according to three different prevalence estimates of the
disease provided by the stakeholders involved in this review.
Results
Electronic searches yielded 2536 references from the selected databases. In addition, we
obtained 186 additional references searching in other resources (Fig 1). Our initial screening
of titles and abstracts identified 171 references to assess in full text. We excluded 137 studies
Fig 1. PRISMA flow diagram.
https://doi.org/10.1371/journal.pone.0242958.g001
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mostly due to: a) ineligible setting (no initial SARS-CoV-2 testing); b) incomplete or no data
about false-negative cases and COVID-19 confirmed cases; c) ineligible population (i.e. pool-
ing sample, analysis based on samples instead of patients) (S3 File). The between reviewers
agreement in the selection of references in the title & abstract stage was moderate (kappa statis-
tic = 0.56), while the agreement in the full-text selection was substantial (kappa statistic = 0.75).
We included 34 studies in our synthesis [34–67] that dealt with 12057 patients (Fig 1).
The sample sizes ranged from 18 to 5,700 COVID-19 confirmed cases (median 90; inter-
quartile range–IQR = 46.5 to 204). Twelve studies focused on the estimation of diagnostic test
accuracy of alternative tests in populations with suspected COVID-19 at the beginning of the
study [34, 37–41, 44, 46, 47, 51, 57, 65]. The remaining studies reported information from case
series, most of which included confirmed cases of COVID-19 at the beginning of the study
[35, 36, 42, 43, 45, 48–50, 52–56, 58–64, 66, 67]. One study focused its data collection only on
children [53] and other only on healthcare workers [48].
Data collection from cases ranged from January 1 [58] to April 15, 2020 [41, 48]; two studies
did not provide complete information about the time of recruitment [35, 45]. Ten studies were
carried out in institutions outside of China [35, 37, 41, 45, 46, 48, 49, 52, 54, 61]. The age of
participants was reported in different ways in 21 studies providing information of COVID-19
confirmed cases [38–45, 47, 51, 53–55, 58, 59, 61–65, 67]: for studies reporting a mean, the
average ranged from 2.5 [53] to 56 years [58], while for studies reporting medians, the corre-
sponding range was 45 [44] to 63 years [54]. These 21 studies reported a total of 5331 men and
4067 women (Table 1).
In all cases, the presence of infection was confirmed after detection of SARS-CoV-2 RNA in
any real-time RT-PCR assay that was repeated after a negative result. The specimens collected
for the RT-PCR assessment were heterogeneous in most of the included studies; in 13 studies
the authors reported the use of nasopharyngeal swabs [35–38, 45–47, 49, 52, 54, 58, 61, 66],
along with oropharyngeal swabs in seven of these 13 studies [35–38, 45–47] (Table 1). The
name/brand of the SARS-CoV-2 nucleic acid detection kit used was reported by 19 studies
[34–37, 46–52, 55, 56, 58, 59, 61–63, 65], and 13 studies reported the target genes under assess-
ment for positivity [35, 46, 49–52, 55, 56, 58, 59, 61, 63, 65], with the ORF1ab being the most
frequently used (8 studies). Ten studies provided heterogeneous information about the time
from the symptom onset to initial testing [35, 36, 39, 40, 43, 44, 49, 51, 61, 65] (Table 1).
Quality of included studies
After classification with the QUADAS-2 tool (Fig 2 and S4 File), the domain most affected
by a high risk of bias was the flow and timing domain, as some studies had not repeated the
RT-PCR testing to all patients with negative results at initial testing [37, 45, 46, 52, 54, 55];
besides, some studies did not provide information about the interval of time for the administra-
tion of a new RT-PCR assay. In the patient selection domain, the risk of bias and applicability
concerns were judged as high or unclear for several studies in which participant selection was
driven by prior testing with RT-PCR, Chest CT findings or serology tests. In most of the studies
it was unclear if a standard testing protocol was used, or if authors restricted participant sam-
pling to those who had received all test [34–36, 38–41, 47, 48, 51, 53, 57, 58, 60, 64, 67].
In the index test domain, several studies lacked to provide details about the criteria for posi-
tive results, such as the target genes under assessment of the SARS-CoV-2 nucleic acid detec-
tion kit used, so that their risk of bias and applicability remained unclear [34, 36–45, 47, 48, 50,
51, 53, 54, 57, 60, 64, 66, 67]. Finally, two studies were judged at unclear risk of bias and appli-
cability in the reference standard domain, since the authors did not report the characteristics
of the repeated RT-PCR and their administration in sufficient detail [39, 52]. Six studies were
PLOS ONE Systematic review about false-negative of initial RT-PCR for COVID-19 diagnosis
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Table 1. Characteristics of included studies.
ID Data
collection
Country Setting Age (years) % Male:
%
Female
Type of specimen RT-PCR Brand Target
genes
Days from
symptoms
onset (days)
Ai T 2020
[34]
January 6-
February 6
China Tongji Hospital of
Tongji MedicalCollege
of Huazhong
University of Science
and Technology,
Wuhan, Hubei, China
Mean
51 ± 15
46:54 b Throat swab • TaqMan One-Step
RT-PCR Kits from
Shanghai Huirui
Biotechnology Co.,
Ltd
Not
reported
Not reported
Range from
2 to 95 b
• Shanghai BioGerm
Medical
Biotechnology Co.,
Ltd
Albert E
2020 [35]
Unclear-
April 14
Spain Hospital Clı́nico
Universitario of
Valencia
Median 65
years; range
from 3 to 98
c
57:43 c Nasopharyngeal or
oropharyngeal
swabs, upper RT
samples
• LightMix Modular
SARS-CoV-2
(COVID-19) E-gene/
LightMix Modular
SARS-CoV-2
(COVID-19) RdRP
gene from TIB
MOLBIOL GmHD
E, RdRp,
S
Median 5
days; range:
1–14 days
• SARS-CoV-2 Real-
time PCR Kit from
Vircell Diagnostics
• SARS-CoV-2 (S
gene)–BD Max
System (Viasure
Real-Time PCR
Detection Kits;
CerTest, Zaragoza,
Spain).
Bernheim A
2020 [36]
January 18-
February 2
China Hospitals from four
provinces in China:
Nanchang (Jiangxi
Province), Zhuhai
(Guangdong
Province), Chengdu
(Sichuan province)
and Guilin (Guangxi
province)
Mean 45
±15,6 b
50:50 b Bronchoalveolar
lavage, endotracheal
aspirate,
nasopharyngeal
swab, or
oropharyngeal swab
• Sansure Biotech
Inc. (Changsha,
China), Shanghai
Zhijiang
Biotechnology Co.
(Shanghai, China),
Not
reported
Range from
0 to 12
• Da An Gene Co.
(Guangzhou, China).
Besutti G
2020 [37]
March 13–23 Italy AUSL-IRCCS di
Reggio Emilia, Reggio
Emilia, Italy
Mean
59 ± 15.8 b
59:41 b Nasopharyngeal and
oropharyngeal
swabs
GeneFinder™
COVID -19 PLUS
Real Real Amp Kit
Not
reported
Not reported
Chen D
2020 [38]
January
19-February
20
China Five non-specialised
infectious disease
hospitals in
Guangzhou
Mean
49.7 ± 15.7 a
43:57 a Nasopharyngeal or
oropharyngeal
swabs
Not reported Not
reported
Not reported
Chen HJ
2020 [39]
January
26-February
4
China Hainan General
Hospital
Mean
54.5 ± 11.8 a
68:32 a Not reported Not reported Not
reported
Mean
6,3 ± 5,6
days
Chen ZH
2020 [40]
January
24-February
6
China The Hangzhou Xixi
Hospital Affiliated to
Zhejiang Chinese
Medical University
Mean
46.9 ± 11.1 a
55:45 a Not reported Not reported Not
reported
Mean 2;
range 1 to
4,5 days
Çinkooğlu
A 2020 [41]
March
15-April 15
Turkey Ege University Faculty
of Medicine
Means from
39.9 to 51 a
47:53 a Not reported Not reported Not
reported
Not reported
Dai H 2020
[42]
January
10-February
7
China 13 hospitals in Jiangsu Mean
44.6 ± 14.8 a
58:42 a Respiratory samples Not reported Not
reported
Not reported
(Continued)
PLOS ONE Systematic review about false-negative of initial RT-PCR for COVID-19 diagnosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0242958 December 10, 2020 7 / 19
Table 1. (Continued)
ID Data
collection
Country Setting Age (years) % Male:
%
Female
Type of specimen RT-PCR Brand Target
genes
Days from
symptoms
onset (days)
Duan X
2020 [43]
January
10-February
8
China The First Affiliated
Hospital, College of
Clinical Medicine,
Medical College of
Henan University of
Science and
Technology, Luoyang
Mean
52 ± 19.3 a
60:40 a Nasal and
pharyngeal swab
specimens
Not reported Not
reported
Mean
6,64 ± 3,82
days
Fang Y 2020
[44]
January
19-February
4
China Taizhou Enze Medical
Center (Group) Enze
Hospital, China
Median 45; 57:43 a Throat swab,
sputum
Not reported Not
reported
Mean 3±3
IQR: 39–55
a
Fechner C
2020 [45]
Unclear Switzerland Cantonal Hospital
Lucerne
Mean
63 ± 15.7 a
75:25 a Nasopharyngeal or
oropharyngeal
swabs
Not reported Not
reported
Not reported
Gietema
2020 [46]
March 13–24 Netherlands Maastricht University
Medical Centre
(MUMC+), the
Netherlands
Median 66;
IQR: 55–76
b
59:41 b Nasopharyngeal
and/or
oropharyngeal swab
• Tib-Molbiol
(Berlin, Germany)
RdRp, E Not reported
• Biolegio
(Netherlands)
He JL 2020
[68]
January 10 –
February 28
China University of Hong
Kong-Shenzhen
Hospital, China
Median 52;
range: 8 to
74 a
50:50 a Nasopharyngeal
swab, oropharyngeal
swab, endotracheal
aspirate, or
bronchoalveolar
lavage
BGI Genomics
(Shenzhen, China)
Not
reported
Not reported
Lan FY
2020 [48]
March
9-April 15
USA Massachusetts
community healthcare
system
Mean
43.6 ± 12.9 b
21:79 b Nasopharyngeal
swabs
• CDC 2019-Novel
RT-PCR
Not
reported
Not reported
• Roche Cobas
SARS-CoV-2
• Abbott Real Time
SARS-CoV-2
Lee TH
2020 [49]
January-
February 29
Singapore National Centre for
Infectious Diseases,
Singapore
Not
reported
Not
reported
Nasopharyngeal
swabs, sputum, and
stool if diarrhoea is
present
• Laboratory
developed test
N
+ORF1ab
Median 5
days; range
from 1 to 24
days
• A�STAR Fortitude
Kit (Accelerate
Technologies,
Singapore)
Li Y 2020
[50]
February
2–17
China Hankou Hospital of
Wuhan, China
Median 57;
range: 22 to
88 b
56:44 b Pharyngeal swab
specimens
Shengxiang
Biotechnology Co
(novel coronavirus
2019-nCoV nucleic
acid detection kit
(fluorescence PCR
method) d
ORF1ab d Not reported
Long C
2020 [51]
January
20-February
8
China Yichang Yiling
Hospital, China
Mean 44,8
±18,2 a
56:44 a Not reported DAAN GENE d ORF1ab d Only
duration of
fever
reported:
2,6 ± 1,7
days
(Continued)
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Table 1. (Continued)
ID Data
collection
Country Setting Age (years) % Male:
%
Female
Type of specimen RT-PCR Brand Target
genes
Days from
symptoms
onset (days)
Long DR
2020 [52]
March 2–30 USA University of
Washington Virology
clinical laboratory
Means from
56.7 to 61.6
c
57:43 c Nasopharyngeal
swabs
• Laboratory-
developed test (LDT)
two-target/two-
control assay
modified from the
CDC
N1, N2,
ORF1ab,
E, S
Not reported
• Panther Fusion
SARS-CoV-2 assay
(Hologic,
Marlborough, MA,
target genes two
conserved regions of
ORF1ab);
• Roche RT-PCR
(Basel, Switzerland,
target E gene)
• DiaSorin (Saluggia,
Italy, target ORF1ab
and S genes).
Ma H 2020
[53]
January
21-February
14
China Wuhan Children’s
Hospital
Mean 2.5;
range: 0.9 to
7 a
56:44 a Not reported Not reported Not
reported
Not reported
Richardson
2020 [54]
March
1-April 4
USA 12 hospitals in New
York City, Long
Island, and
Westchester County,
New York (Northwell
Health system), USA
Median 63;
IQR: 52–75
a
60:40 a Nasopharyngeal
swabs
Not reported Not
reported
Not reported
Shen N
2020 [55]
January
22-February
18
China Tongji Hospital in
Wuhan
Median 56;
IQR: 42–66
49:51 Throat swabs SARS-CoV-2 nucleic
acid detection kit
(Shanghai Huirui
Biotechnology Co.
Ltd)
N
+ORF1ab
Not reported
Wang P
2020 [56]
January
25-March 16
China First People’s Hospital
of Jingmen, Hubei
Province
Median 58;
range: 21–
95
46:54 Throat swabs RT-PCR reagent
BioGerm (Shanghai
BioGerm Medical
Technology Co.,
Ltd.)
N
+ORF1ab
Not reported
Wen Z 2020
[57]
January
21-February
14
China Two areas in Henan
Province, China
Median 16;
range: 12 to
98 b
47:53 b throat-swab,
sputum, or alveolar
lavage fluid
specimens
Not reported Not
reported
Not reported
Wong HYF
2020 [58]
January
1-March 5
China Four tertiary and
regional hospitals in
Hong Kong (Queen
Mary Hospital, Pamela
Youde Nethersole
Eastern Hospital,
Queen Elizabeth
Hospital, and
Ruttonjee Hospital),
China
Mean 56;
range: 16 to
96 a
41:59 a nasopharyngeal
swabs and throat
swabs
QuantiNova Probe
RT-PCR Kit
(QIAGEN, Hilden,
Germany)
RdRp Not reported
Wu J 2020
[59]
January
22-February
14
China First People’s Hospital
of Yancheng City, the
Second People’s
Hospital of Yancheng
City, and the Fifth
People’s Hospital of
Wuxi, China
Median
46.1; IQR:
30.7 to 61.5
49:51 nose swab and/or
throat swab
Bio-germ, Shanghai,
China
N
+ORF1ab
Not reported
(Continued)
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considered as at low risk of bias in all QUADAS-II domains assessed [49, 56, 59, 61, 62, 65],
while 20 were considered as at unclear risk due to at least one domain was judged with unclear
risk of bias. The remaining eight studies were considered high risk of bias as at least one
domain was judged at high risk [37, 38, 46, 51, 52, 54, 55, 63].
The assessment of limitations using the adapted JBI case-series tool provided a similar pic-
ture owing to the uncertainty regarding the consecutive inclusion of patients and follow-up
time after the first RT-PCR result (S4 File). Additionally, due to the selection of patients, the
majority of included studies were not an adequate sample of the target population (S4 File).
Table 1. (Continued)
ID Data
collection
Country Setting Age (years) % Male:
%
Female
Type of specimen RT-PCR Brand Target
genes
Days from
symptoms
onset (days)
Xie X 2020
[60]
January
16-February
2
China Database of Radiology
Quality Control
Centre, Hunan/ 3
cities in Hunan
Province, China
Not
reported
Not
reported
swab test; no further
details provided
Not reported Not
reported
Not reported
Young BE
2020 [61]
January
23-February
3
Singapore 4 hospitals in
Singapore
Median 47;
range: 31–
73 a
50:50 a Nasopharyngeal
swabs
QuantiTect Probe
RT-PCR kit
(Qiagen)
N, S,
ORF1ab
Median 13;
range 5–24
days
Zhang H
2020 [62]
January
22-February
28
China Huanggang Central
Hospital and The
Second Affiliated
Hospital of Shandong
First Medical
University
Median
48.3; IQR:
33–56 a
56:44 a Not reported The Beijing
Genomics Institute
(BGI, Beijing, China)
Not
reported
Not reported
Zhang JJ
2020 [63]
December
29-February
16
China Zhongnan Hospital of
Wuhan University and
No.7 hospital of
Wuhan, China
Median 57;
range: 22 to
88 a
53:47 a Pharyngeal swab Shanghai bio-germ
Medical Technology
Co Ltd
N
+ORF1ab
Not reported
Zhao JJ [64] January
11-February
9
China Shenzhen Third
People’s Hospital
Median 48;
IQR: 35–61
a
49:51 a Throat swabs, Nasal
swabs
Not reported Not
reported
Not reported
Zhifeng
2020 [65]
January
25-February
6
China Xiaogan Central
Hospital, China
Range: 23 to
82 a
59:41 a Throat swabs Multiple brands d N
+ORF1ab
Mean 6,5
days d
Zhou H
2020 [66]
January
19-February
15
China First Affiliated
Hospital, Zhejiang
University School of
Medicine
Mean 53.3;
range: 14–
96 c
59:41 c Bronchoalveolar
lavage, endotracheal
aspirate, or
nasopharyngeal
swab
Not reported Not
reported
Not reported
Zhou S 2020
[67]
January
16-February
12
China Tongji Hospital of
Tongji Medical
College, Huazhong
University of Science
and Technology
Mean
52.3 ± 13.1 a
54:46 a Pharyngeal swab Not reported Not
reported
Not reported
Notes:
a) Information from COVID-19 confirmed cases only;
b) Information from COVID-19 suspected (positive and negative);
c) information from other groups reported by the authors;
d) data provided by the corresponding author (personal communication).
CDC: Center for Disease Control and Prevention; LDT: Laboratory-developed test; ORF1ab: Open Reading Frame 1ab; RdRp gene: RNA polymerase gene; RT-PCR:
Reverse transcription polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
https://doi.org/10.1371/journal.pone.0242958.t001
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Findings
We analysed information from 34 studies collecting information from 12,057 patients con-
firmed to have SARS-CoV-2 infection and 1060 cases with RT-PCR negative findings in their
initial assessment. False-negative rates ranged from 0.018 [45] to 0.58 [57], with a median of
0.11 (Fig 2).
The summary estimate of the false-negative rate was 0.13 (95% CI 0.09 to 0.19). The data
were characterised by a considerable between-study heterogeneity, the 90% prediction interval
ranged from 0.02 to 0.54 (tau-squared = 1.39).
Assessment of the effect of potential sources of heterogeneity was limited because stratified
information for relevant subgroups was not available in most studies (Table 2). There were no
Fig 2. Forest plot included studies. Notes: FN= False-negative; TN= True negative. QUAOAS-II assessment: D1=
risk of bias- patient selection; A1= applicability- patient selection; D2= risk of bias- index test; A2= applicability- index
test; D3= risk o f bias- reference standard; A3= applicability- reference standard; D4= risk of bias-flow and timing.
Green bullets= low risk of bias; yellow bullets= unclear risk of bias; red bullets= high risk of bias.
https://doi.org/10.1371/journal.pone.0242958.g002
Table 2. Assessment of sources of heterogeneity.
Variable Number of studies (patients) Heterogeneity (Tau-squared) P-value
Days of symptoms (average/median) Less than 5 days 3 (120) 0.01 0.145
Five days or more 6 (817) 0.87
PCR target N gene 8 (2911) 1.09 0.448
No N gene 5 (615) 0.30
ORF1ab gene 10 (3188) 0.91 0.144
No ORF1ab gene 3 (338) 0.00
Country China 24 (4798) 1.31 0.002
Other countries 10 (7259) 0.36
Type of design Accuracy 12 (1798) 1.52 0.407
Case series 22 (10259) 1.28
Risk of bias High risk 8 (8947) 0.79 Reference
Unclear risk 20 (2549) 1.31 0.357
Low risk 6 (561) 0.60 0.004
https://doi.org/10.1371/journal.pone.0242958.t002
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differences related to the duration of symptoms at the time of first RT-PCR test based on infor-
mation derived from nine studies provided means and medians of symptoms onset (Table 2).
Comparison of false-negative rates of studies using different RT-PCR kits targetting (nucleocap-
side N-gene and/or ORF1ab gene) makes no significant differences (Table 2). In addition, most
studies (28 out of 34) reported a mix of specimen types collected for RT-PCR assessment; those
reporting the use of nasopharyngeal swabs provided a range of false-negative from 0.018 to 0.33,
while those reporting the additional use of oropharyngeal swabs reported a range of false-nega-
tive from 0.02 to 0.33. The analysis by country (China versus other countries) showed a potential
effect on the summary estimations; the pooled estimate in non-Chinese countries was 0.06 (CI
95% = 0.04 to 0.09; 90% prediction interval 0.02 to 0.17; tau-squared = 0.36). Using meta-regres-
sion, we found a positive association of country with the false-negative rate (Table 2).
Additional post-hoc analysis by type of study did not provide a reduction of the observed
heterogeneity (accuracy studies = 0.16, 95% CI 0.08 to 0.28, tau-squared = 1.52; case-
series = 0.12, 95% CI 0.08 to 0.18, tau-square = 1.28). The false-negative proportion seemed
higher in studies assessing test accuracy than in case series, although confidence intervals over-
lapped. An analysis by the global risk of bias (based on the QUADAS-II domains) showed a
difference between high risk versus low-risk studies (high-risk studies = 0.08, 95% CI 0.04 to
0.14, tau-square = 0.79; low-risk studies = 0.33, 95% CI 0.20 to 0.49, Tau-square = 0.60),
although the heterogeneity remains similar to those reported for the total group (Table 2).
Summary of findings under the GRADE approach
Since we could not warrant that the average estimates from the meta-analysis were valid and rep-
resentative estimates of the true value of the false-negative proportion in the current practice, we
used the estimated predictive interval in the analysis of the certainty of the evidence, using the
GRADE approach. We illustrated the consequences of the range of false-negative rates in a popu-
lation of 100 tested, according to three different prevalence estimates seen in current clinical prac-
tice by participant stakeholders and similar to those estimated by the included studies (10%, 30%,
and 50%) (Fig 3). Using a prevalence of 50%, we found that 1 to 27 cases would be misdiagnosed
and would not receive adequate clinical management; in addition, they could require repeated
testing at some point in their hospitalisation or require another testing for competing diagnoses.
The quality of the evidence was judged to be very low due to issues related to the risk of bias, indi-
rectness, and inconsistency (Fig 3). This numerical approach should be interpreted with caution
due to the multiple limitations of the evidence described above (Fig 3).
Discussion
Our systematic review identified 34 studies and 12,507 participants providing information
about the proportion of false-negative (FN) cases in the detection of SARS-CoV-2 by RT-PCR
assays at first use. Individual studies estimates of false-negative rate ranged from 0.018 to 0.58.
Fig 3. Summary of findings (GRADE assessment). Notes= 1) Evidence downgraded one level due to risk of bias
issues: multiple unclear risk related to patient selection and index test, several studies at high risk of bias in flow and
timing Domain; 2) Evidence downgraded one level due to indirectness: unclear or high concerns about applicability of
selected populations enrolled in studies; 3) Evidence downgraded one level due to inconsistency: tausquare =1.39.
https://doi.org/10.1371/journal.pone.0242958.g003
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Included studies were affected by several sources of potential bias, especially related to testing
protocol to rule in/rule out the presence of SARS-CoV-2 infection, the analysis of a selected
sample of COVID-19 patients, as well as the unclear report of key index test characteristics.
The meta-analysis of the FN rates showed a considerable between study variability in esti-
mates, which was not explained by any of the protocol defined characteristics. This variability
is a limitation for the interpretation of the summary estimate of the proportion of the FN test
results. Kucirka et al. also detected similar uncertainties in their bayesian modelling of false-
negative rates of RT-PCR by time since exposure, based on information from seven studies
and 1330 respiratory samples [69]. As an alternative, we illustrated the impact of heterogeneity
by showing the number of false-negative cases expected in a cohort of 100 patients tested
under three different prevalence of the disease scenarios. We based our calculations on the
limits of the false-negative prediction interval. Using a prevalence of 50%, we found that in
100 persons tested, up to 27 cases would be misdiagnosed, putting them at risk of not receiving
adequate clinical management or delaying isolation. We emphasised that these numerical
approaches should be interpreted with caution due to very-low quality of evidence.
Our systematic review faced other challenges in its development. First, our study was initially
planned as a rapid review aiming to provide a quick response to our local clinicians at the begin-
ning of the COVID-19 pandemic. Due to the permanent involvement of clinicians managing
COVID-19 patients at this point, we were able to define a review question that responds to a clini-
cal inquiry relevant to current clinical practice [70–72]. However, due to the increasing number
of publications potentially eligible to answer the review question, our approach evolved into a liv-
ing-systematic review with regular updates of the evidence. This manuscript reflects the third
update of our literature searches with information current up to July 2020. To promote transpar-
ency in the development of this review, we have uploaded our previous results in the Open Sci-
ence Framework repository for public consultation (https://tinyurl.com/vvbgqya).
A second challenge is related to the type of studies providing information about the false-
negative rate associated with RT-PCR at initial testing. We expected to find studies specifically
aimed to estimate the number of initial negative results of RT-PCR assays, with further confir-
mation of SARS-Cov-2 infection with an additional RT-PCR within the following days to the
first result. On the contrary, we found that the reporting of false-negative rate was not the pri-
mary aim of any of the include studies. In some cases, these Figs were reported as descriptive
statistics of the collected sample. Although we carried out a comprehensive and sensitive
search strategy including major databases and repositories of preprint publications, we cannot
discard that some eligible studies have not been identified yet due to the limitation of the
reporting in key study sections, such as the abstract and methods.
Finally, as we have remarked in the findings section of this review, we found a considerable
heterogeneity in the data insufficiently explained by the statistical analysis performed. Suggested
sources of heterogeneity such as the type of specimen collected, the time to onset of symptoms
(as an approach to viral load), as well as the name of the RT-PCR kit used, were partially or not
reported at all by the included studies. This variability on COVID-19 testing data and the chal-
lenge to provide a pooled estimation with a useful clinical meaning have been previously
remarked as the main constraint in the development of systematic reviews on this field [73].
Despite our efforts in the analysis of data, we only were able to find some reduction of this vari-
ability comparing those studies performed in China versus those carried out in other countries
(i.e. USA, Singapore, and the Netherlands). We believe that information provided by Chinese
studies reflects early experiences with the diagnosis of COVID-19; their findings are probably
affected by several unreported issues, such as the RT-PCR kits in use (likely the first kits devel-
oped for SARS-CoV-2 detection), the lack of standardised methods for COVID-19 testing and,
in general, the limited knowledge about this new infection at the beginning of 2020.
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Despite the heterogeneous data available to address the review question, our study involved a
rigorous assessment of potential sources of bias and applicability concerns, a formal statistical
analysis and a final evaluation of the certainty of the evidence using a well-known system
(GRADE). Although not all studies included in this review were accuracy studies, we decided to
apply the QUADAS-II tool regardless of the type of design. However, even though QUADAS-II
was not developed to evaluate case series, we preferred to standardise the quality assessment to
report on a common pool of issues. We added the assessment of all studies as an appendix, using
an adapted checklist tool for case-series to provide complementary information to this assess-
ment. Due to the multiple difficulties associated with the lack of reporting of included studies,
and due to the high probability of new studies being published in the short-term, we provided
some recommendations for future studies candidates to be included in an update of this review:
• Inclusion of a series of consecutive patients instead of selected groups, to avoid spectrum bias.
• Description of RT-PCR scheme in use, including target genes under assessment and positiv-
ity criteria.
• Description of preanalytical steps (conservation of samples, time until being sent to the labo-
ratory, training of personal).
• Clear reporting of the time since the onset of symptoms, especially for those patients with
clinical findings at admission
• Reporting of the number of additional RT-PCR assays performed
• Details about the application of the reference standard, including the time of administration
after the index test (initial RT-PCR)
• If possible, database sharing could allow re-analyses by independent researchers, including
individual-patient data (IPD)-meta-analysis and increasing thus the confidence on the new
evidence
• Adding serological samples to a cohort of individuals with compatible symptoms and nega-
tive PCR to warrant an independent verification of infection.
Conclusions
Our findings reinforce the need for repeated testing in patients with suspicion of being
infected, due to either clinical or epidemiological reasons, given that up to 54% of COVID-19
patients may have an initial negative RT-PCR result (certainty of evidence: very low). The col-
lected evidence has several limitations in terms of risk of bias and applicability. Incomplete
reporting of several key factors hampered a comprehensive analysis of collected data. An
update of this review is warrented when additional studies become available.
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